<DOC>
	<DOC>NCT01015911</DOC>
	<brief_summary>This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in patients with CD70-positive relapsed or refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.</brief_summary>
	<brief_title>A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Pathologicallyconfirmed diagnosis of NHL or RCC Relapsed, refractory, or progressive disease following at least 1 prior systemic therapy Confirmed CD70 expression Measurable disease, defined as at least 1 lesion &gt;1.5 cm in the greatest transverse diameter for patients with NHL, and at least 1 nonresectable tumor lesion &gt; or equal to 10 mm in diameter for patients with RCC Previously received an allogeneic transplant History of another primary malignancy that has not been in remission for at least 3 years Prior antiCD70directed therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD70</keyword>
	<keyword>Lymphoma, Non-Hodgkin</keyword>
	<keyword>Carcinoma, Renal Cell</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>monomethylauristatin F</keyword>
</DOC>